Regeneron Pharmaceuticals (NASDAQ:REGN) Lowered to "Hold" Rating by Wall Street Zen

2026-03-11 03:14:50

Abstract generation in progress

Wall Street Zen has downgraded Regeneron Pharmaceuticals (NASDAQ:REGN) from a “buy” to a “hold” rating, despite the company’s recent earnings beat and an average analyst target price of $802.27 indicating a “Moderate Buy” consensus. Several other analysts have recently raised their price targets for REGN. The biopharmaceutical company recently reported strong quarterly earnings, surpassing analyst estimates for both EPS and revenue, but has also seen insider stock sales totaling over $4.14 million in the last 90 days.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.